Actively Recruiting
Comparison of Furosemide Versus Albumin Plus Furosemide in Increasing Urine Output in Critically Ill Patients: A Double-Blind Randomized Clinical Trial
Led by Jose J Zaragoza, MD MSc · Updated on 2026-02-18
56
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of furosemide alone compared to furosemide combined with albumin in adult critically ill patients with fluid overload. The study aims to find out if adding albumin improves urine output and kidney function. The primary focus includes measuring urine output at 2 hours and examining changes in kidney blood flow markers and biochemical tests. Secondary measures include blood pressure, electrolyte levels, and kidney resistance patterns. Participants are randomly assigned to one of two groups: one receives a single intravenous dose of furosemide at 1 mg/kg infused over 30 minutes with a placebo saline infusion, while the other receives the same dose of furosemide combined with 50 grams of 25% albumin infused over 30 minutes. This double-blind trial ensures both groups are treated under similar controlled conditions to compare the treatments effectively. During the study, urine output is measured at 2 hours after treatment administration. Researchers also use bedside ultrasound to assess fluid overload and venous congestion, while monitoring blood pressure, electrolyte changes, and kidney function through blood and urine tests up to 24 hours. The study helps determine whether albumin enhances diuretic response and kidney health in this patient group. Participation lasts through these initial assessments and monitoring periods.
CONDITIONS
Brief Title
"Effect of Albumin Combined With Furosemide in Critically Ill Patients With Fluid Overload: Impact on Urine Output and Renal Function"
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years of age admitted to the intensive care unit (ICU) without mechanical ventilation.
- Patients for whom diuretic therapy will be initiated for the first time during the ICU stay due to clinical signs of fluid overload, as determined by the treating physician.
You will not qualify if you...
- Patients or family members who refuse participation in the study.
- Patients receiving palliative care.
- Patients with kidney failure requiring renal replacement therapy.
- Patients currently participating in another clinical research protocol.
- Patients with clinical evidence of hypovolemia or dehydration.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Single day treatment with assessments up to 24 hours
Participants receive either furosemide alone or furosemide combined with albumin to manage fluid overload.
1 treatment visit with assessments over 24 hours
Trial Site Locations
Total: 1 location
1
76000
Querétaro City, Querétaro, Mexico, 26089
Actively Recruiting
Research Team
A
Alina Elizabeth Arechiga Casas, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here